

SEN

701400

U.S. OFFICIAL MAIL
PENALTY FOR
PRIVATE USE \$300
02 1A
0004205065
MAILED FROM ZIP CODE 22314




\$ 00.83⁰
SEP 23 2005

AN EQUAL OPPORTUNITY EMPLOYER

P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS



RECEIVED
SEP 28 2005
USPTO MAIL CENTER

BEST AVAILABLE COPY

ITN -



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/834,307	04/12/2001	Richard J. Whitbourne	32286-192724	3036

26694 7590 09/23/2005

VENABLE LLP
P.O. BOX 34385
WASHINGTON, DC 20045-9998

RECEIVED
OIPE/IAP

SEP 27 2005

EXAMINER

YOUNG, MICAH PAUL

ART UNIT	PAPER NUMBER
----------	--------------

1618

DATE MAILED: 09/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/834,307

Applicant(s)

WHITBOURNE ET AL.

Examiner

Micah-Paul Young

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 July 2005.
2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 23-74 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 23-74 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

Acknowledgment of Papers Received: Amendment/Response dated 7/1/05

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

3. Claims 23-25, 28-52, 56-58, 61-65, 67-71 and 74 are rejected under 35 U.S.C. 103(a) as being unpatentable over the disclosures of Whitbourne et al (USPN 6,110,483 hereafter '483).

The claims are drawn to a medicated device comprising a scaffold with surfaces in close proximity, and a coating on said surface comprising a therapeutic agent.

4. The '483 patent discloses a medical device comprising a substrate with a coating (abstract, col. 5, lin. 58-65). The substrates include commonly difficult substrates to coat such as wires, needles, urethral inserts and other implantable objects (*Ibid.*). The coating material comprises both hydrophilic and hydrophobic polymers such as N-vinylpyrrolidone (col. 5, lin.

Art Unit: 1618

13-39) and acrylic polymers (col. 6, lin. 5-16) as well as vinyl acetate (*Ibid.*), as well as polyvinylpyrrolidone/vinyl acetate copolymers (col. 3, lin. 38-50). The coating comprises pharmaceutical agents including rifamycin, and heparin complexes with benzalkonium chloride (col. 8, lin. 59-col. 9, lin. 28). The coatings, as a result of the drying process, intermingle with the substrates (col. 10, lin. 36-40). The coating composition has a thickness of about less than 50 microns (col. 7, lin. 15-20). According to applicant's specification a 10-micron thick coating would correspond to a 1000 microgram/cm³. The thickness of this coating would possess a loading amount well within the limits of the claimed invention. The reference discloses various methods of making the medical device including dipping, spraying and other well-known coating methods (col. 2, lin. 60-68). Though silent to the specific design of the substrates regarding their edges and surfaces, the coating is a continuous coating over each surface (col. 4, lin. 18-30). Applicant is invited to provide evidence that the continuous coating of the invention does onto cover the edges and bridge surfaces.

5. Regarding claims 41 and 42, it is the position of the examiner that such limitations do not impart patentability to the claim. The reference discloses a polyvinylpyrrolidone/vinyl acetate copolymer as a possible coating material. It would be well within the limits of ordinary skill in the art to determine the optimal component ranges operation for the polymer coating giving the general conditions of the specification. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. *See In re Aller*, 220 F.2d 454 105 USPQ 233, 235 (CCPA 1955).

6. Furthermore the claims differ from the reference by reciting various concentrations of the active ingredient(s). However, the preparation of various compositions having various amounts

Art Unit: 1618

of the active is within the level of skill of one having ordinary skill in the art at the time of the invention. It has also been held that the mere selection of proportions and ranges is not patentable absent a showing of criticality. *See In re Russell*, 439 F.2d 1228 169.USPQ 426 (CCPA 1971).

7. With these things in mind it would have been obvious to a skilled artisan to follow the suggestions of the art to produce a medical article with a continuous coating over all surfaces with a high loading concentration. One of ordinary skill in the art would have been motivated to follow these suggestions in order to provide a coated medical device that is flexible, and resist wet abrasions. It would have been obvious to follow these suggestions with an expected result of a coated medical device.

8. Claims 26,27,53-55, 59, 60, 66, 67, 72 and 73 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Whitbourne et al (USPN 6,110,483 hereafter '483), Kamath et al (USPN 6,335,029 hereafter '029) and Khan et al (USPN 5,589,120 hereafter '120). The claims are drawn to a medical device comprising a substrate and a coating. The substrate is a coil, and the coating further comprises paclitaxel and other active agents.

9. As discussed above the '483 patent discloses a medical device comprising a substrate and a coating. The substrates include wires, stents, and other implants (col. 2, lin. 31-38). The reference is however silent to the inclusion of coils as possible substrates. The reference is also silence to the inclusion of paclitaxel. However the inclusion of this antibiotic is well within the level of skill in the art, since many antibiotic agents are mentioned and suggested by the '483 reference. Their inclusion in a medical device is well within the art as seen in the '029 reference.

Art Unit: 1618

10. The '029 reference discloses a coated medical device comprising a substrate and a coating with antibiotics agent incorporated therein (abstract). The substrates may include coils, (col. 2, lin. 45-50), biocompatible polymer coatings such as polyvinylpyrrolidone (col. 6, lin. 28-50), and antibiotics such as paclitaxel (col. 5, lin. 54-65). Following these teachings a skilled artisan would have been motivated to include paclitaxel in to the coating compositions of '483. A skilled artisan would have further been motivated to apply the coatings to a coiled substrate following the suggestions of '029.

11. Likewise as shown in the '120 reference, which teaches a coated implant comprising various antibiotics such as polyhexamethylene biguanide hydrochloride (col. 3, lin. 51-55). A skilled artisan would have been motivated to combine the agents of the '120 with the coatings in order to impart biocidal properties on the implant of '483.

12. With these things in mind a skilled artisan would have been motivated to apply coating compositions to coiled substrates as taught and suggested by '029, or '120. A skilled artisan would have been motivated to continuously coat the coil as taught by '483 in order to provide a medical device with a coating that is flexible, and resist wet abrasions. A skilled artisan would have been motivated to include paclitaxel into the coatings of '483 as shown in '029 and '120 in order to further treat more bacterial infections. It would have been obvious to a skilled artisan to combine these teachings and suggestions with an expected result of a medical device with a flexible, and stable coating capable of treating various bacterial infections.

Response to Arguments

13. Applicant's arguments filed 7/1/05 have been fully considered but they are not persuasive. Applicant argues that:

- a. The '483 reference does not obviate the claims, and does not teach or suggest a coating that covers the surfaces and edges of an implant
- b. Since the '483 patent does not teach or suggest any of the claims, there is not motivation to combine the reference with other patents.

14. Regarding argument a., it is the position of the Examiner that the reference does in fact obviate the claim invention. The coating of the '483 reference is continuous, and covers the enteric implant, regardless of the shape. Applicant is invited to provide evidence to how a continuous coating would not cover adjacent edges and surfaces. The coatings have identical components, and purposes within the same field of endeavor. Applicant is invited to provide evidence of a patentable distinction and unexpected result from the coating of the instant claims. Regarding the loading amount, as discussed above, when the loading amount is directly related to the thickness of the coating, as defined by applicant. The coating of the '483 reference and its corresponding therapeutic agent loading meets the limitations of the instant claims. Though the reference is silent to the edges and surfaces of the proposed implant, the same shapes and structures are taught (coils, wires, etc.) and the coating is disclosed as continuous. Barring evidence to the contrary, it will remain the position of the Examiner that these disclosures obviate the claims of the instant claims.

15. Regarding argument b., as discussed above, it is the position of the Examiner that the '483 reference obviates the instant claims. The '483 patent provides suggestions for the inclusion of antimicrobial agents into the implant coating. The '120 and '029 references merely provide the specific agents of the instant claims. Their inclusion would be well within the level of ordinary skill in the art, and would be obvious barring a showing of an unexpected result.

Art Unit: 1618

Both supporting reference provide coated implants where biocides and active agents are included into the coating material. These references provide coated implants within the same field of endeavor as that of the instant claims, and sufficiently obviate the instant claims. Applicant is invited to provide evidence of an unexpected result from the combination presented in the instant claims. Until such time, the claims will remain obviated by the prior art.

Conclusion

16. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608. The examiner can normally be reached on M-F 7:00-4:30 every other Monday off.


Art Unit: 1618

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Micah-Paul Young
Examiner
Art Unit 1618


MP Young

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600


Notice of References Cited

Application/Control No.

09/834,307

Applicant(s)/Patent Under
Reexamination
WHITBOURNE ET AL.

Examiner

Micah-Paul Young

Art Unit

1618

Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-5,589,120	12-1996	Khan et al.	264/130
	B	US-6,110,483	08-2000	Whitbourne et al.	424/423
	C	US-6,335,029	01-2002	Kamath et al.	424/423
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.